

Table S4. Percent Inhibition and seroconversion rate against SARS-CoV-2 variant of concerns

Time point	% Inhibition (median, IQR)		P-value	Seroconversion rate (n, %)		P-value
	BNT162b2/ BNT162b2 (N=76)*	BNT162b2/ mRNA1273 (N=16)		BNT162b2/ BNT162b2 (N=76)*	BNT162b2/ mRNA1273 (N=16)	
B.1.1.7 [Alpha]						
4-week after the 3 <sup>rd</sup> dose	96.5 (96.2, 96.7)	96.2 (95.5, 96.7)	0.117	75 (98.7)	16 (100.0)	1.000
Before the 4 <sup>th</sup> dose	86.6 (71.6, 97.2)	82.7 (68.0, 96.0)	0.639	73 (96.1)	16 (100.0)	1.000
4-week after the 4 <sup>th</sup> dose	98.3 (98.1, 98.5)	98.4 (98.1, 98.5)	0.743	75 (100.0)	16 (100.0)	-
B.1.351 [Beta]						
4-week after the 3 <sup>rd</sup> dose	93.8 (92.6, 94.5)	93.3 (91.6, 94.3)	0.356	75 (98.7)	16 (100.0)	1.000
Before the 4 <sup>th</sup> dose	74.4 (58.5, 90.7)	74.9 (48.0, 89.9)	0.753	73 (96.1)	16 (100.0)	1.000
4-week after the 4 <sup>th</sup> dose	97.6 (96.5, 98.0)	97.6 (97.0, 97.9)	0.958	75 (100.0)	16 (100.0)	-
B.1.617.2 [Delta]						
4-week after the 3 <sup>rd</sup> dose	93.8 (92.8, 94.3)	93.5 (91.7, 93.8)	0.089	75 (98.7)	15 (93.8)	0.319
Before the 4 <sup>th</sup> dose	81.6 (63.0, 96.3)	74.1 (55.9, 92.7)	0.365	73 (96.1)	16 (100.0)	1.000
4-week after the 4 <sup>th</sup> dose	98.0 (97.7, 98.4)	98.1 (97.8, 98.5)	0.528	75 (100.0)	16 (100.0)	-
B.1.1.529 [Omicron]						
4-week after the 3 <sup>rd</sup> dose	81.7 (67.3, 91.9)	80.5 (62.7, 87.7)	0.500	70 (92.1)	13 (81.3)	0.187
Before the 4 <sup>th</sup> dose	17.6 (7.8, 39.1)	8.5 (5.6, 25.3)	0.161	25 (32.9)	3 (18.8)	0.374
4-week after the 4 <sup>th</sup> dose	85.3 (72.7, 92.5)	81.2 (72.9, 87.2)	0.370	69 (92.0)	15 (93.8)	1.000

\*N=90 for participants at 4 weeks after the fourth dose